Xcelience has announced that it will be opening a 3,000 square foot facility in Birhmingham, United Kingdom. The facility’s opening makes Xcelience the first small to mid-sized American CDMO to establish an international operation. This facility will allow the company to expand its packaging and distribution business and move into European markets. It will also allow Xcelience to expand its capabilities, including secondary packaging, labeling, and clinical trial distribution operations, as well as qualified person release and lab services.
The facility has already passed regulatory inspection; the UK Medicines and Healthcare Products Regulatory Agency (MHRA) inspected the facility on June 4th.
Derek Hennecke, the president and CEO of Xcelience, spoke about the opening of the new facility. “The market for pharmaceutical products is global, and our clients have been asking us to go global with them. This facility is our first step toward meeting that need,” he said. “Now our clients have a central hub which can be used to package and distribute throughout the UK and European markets.”The company has stated that the Birmingham facility is the first step for the company to move into developing international hubs.
The company is only two years removed from opening a new facility in Tampa, Florida. The facility was designed to perform clinical trial work both in the US and in Europe, which has helped the company to get acclimated to the clinical operations that take place in Europe.
Ted Koontz, the company’s COO, commented on the grand opening of the Tampa facility back in 2012. “By streamlining our services, we can take a molecule from pre-formulation through formulation and clinical manufacturing straight to packaging, labeling, and shipping, all as part of a single project within a single organization,” he said.